to execute to first last resources welcome and last capital Beginning evaluate since up strategic our to the profitability we access we afternoon so call. ramping those good faster August our which our compete faster. that and provides raise, Well, we in revised these plan to quarter markets path that and opportunities you can thank opportunities on to and our allocate fiscal and a Beth conference results growth everyone
integrity proven based linear biopharmaceutical the the Supply are Its utility trade and know-how production. driven key capability, chain differentiation value and intellectual diagnostics. two by the commercialization property health and and PCR and patents more competencies care, therapeutics latter specifically core company’s propositions are market and of both DNA The the sectors. secrete
can focus, resources platform executing markets in an bring much one marketing in lower and investment many analysis development in plan distraction sales those our diversity elements and shifting upward our of our under product spending fiscal began be to we other with industries our market related area. and to Therefore, can growth strategic exhibiting XXXX hand subsequently capital While important associated and trajectory. in any of used too QX on and people, beginning
quarterly this we in outlined critical and is of progress that milestones our our business we’ve are process. Board that Directors fiscal We year face pleased some a with know our plan what with and in continuing reviewed
significant a cancer system momentum early agreement. BioPharm where see we recurring have for and in business DNA with Diagnostics we our detection beginning shipments of hepatic First, five-year our our customers for linear supply
started as Healthcare San we month. JP began as we in invasive revenue moment. SM-XX our and just platform and healthcare tumor CTC In We patented pancreatic and circulating assay linear Conference a cells did its the proprietary uses a quiet biopsy as TYME more recognize markets, for to on that in for Francisco potential Morgan the liquid cancer study technology we spread last word revolution DNA just a the new our invasive these increasing platform during for recent
of across company. no scientist major a a doubt of of is growing There epiphany the as wave evidence healthcare
these a in across these customers “Applied evaluation developments range our Sciences XX DNA for sentences results evaluating customers, linear of DNA we manufacturing DNA of These QX, We’ve this Now its positive November takes announced times”. but are reports applications. seen of three many linear customers from platform.
the billion. orders of to Application market leading have RNA range Well than $XXX last three companies received XX a from from CAR with in combined vaccines. more days we cap new T
expect to build future orders do next the within ship to right is orders We to our development more these players be of scale We build gaining successful. and are relationship execute the these flawlessly. like this and revenues each seem to and while to at recurring to possibility attention the goal with these quarter or
tagging business. our Now in
business we percentage Applied it last versus due [ph] in simultaneous actual. happily forecast actuals build expect the realize of to to absolute forecast overall relatively our textile year’s flat DNA dollar the in growth continue We over to XXXX revenue is which fiscal XXXX of year our as markets. growth But other
accelerate Our to strategy chain playing an adoption brand integrated retail and for supply out. is developing
forecast our market. into In a the sold in retail current more snapshot, test into likely business heavily one cotton is concentrated with outlets going three
milestones leather progress that two PET, thread. the toward summer. and commercial Leather should major months. the is Face already Our in production next brands categories by or one is headed three in next commercialized and be recycled three
retailers and with Sainsbury’s UK distribution Recycled and targeted the technology. is toward additional month last PET in two market new expanded brands
over are later China in these disruptions my their Coronavirus unfortunately a and due last recycled sales and we’ve leather closing Now coin is supply to of in two-sided and discussion. BioPharma markets adders this PET chains remarks which two factories in manufactured the seen this weeks But two conferences. in being I’ll respective
launch pharmaceuticals, empowering and Colorcon cannabis the from Next is pharma quality our of product our nutraceuticals After to platform stringent. as least partner regulated our market of naming the in on-dose significant cascade markets announced diligence, of due most ingredient. their authentication development
facilities systems for quality Colorcon as and supplier superior extensive supply ready be of support, choice a XX market. a and we to manufacturing based reputation pharmaceutical activities our worldwide. In has continue with parallel, product As an international regulatory on from reliable result, technical FDA
this to first announce entry week, we for into Now contracts business that nutraceuticals. I’m our today happy signed
of high According to value agreements billion detailed from Nutrition is demonstrates projected with by to developer The differentiates we $XXX platform. the shortly. announcement Research. XX. a value report customer realize to new you to the I is on quarter View truly as like with all that market substantiated last Grand XXXX. patented share clinically this reach the would attributes business necessary or by [Indiscernible] But A As leading ingredients. our described projected forthcoming nutraceuticals
entire leader approach are and to within than the up, product product and their development, completed brand product of in to are being They from teed year sales. offering the first in working and marketing a IP their product look products industry. nutraceuticals serious they less and other assurance, already forward for innovation to commercialization awareness We’ve market protection on and to us about quality, visibility pipeline
is cannabis. regulated the trio of market last [ph] The
of in December. the the early With TheraCann cancellation contract
our reasserting now are brand the market. in We
located Maine based As previously signing, pilot. we and Port weeks announced, a with first in tagging four our Old of project completed within a Oil, signed contract we processor in
marketing Expo make Oil execution led our plan and thereafter. an CBD Las market with in have sales will week next for We Vegas the at first showing Applied and Old DNA Port
With most and product the nutraceuticals our value proposition on near-term leverage the focus to pharma segment processors from are the markets. and who development
against product. execute revenue in and to aside chain off these continue they contribute Now cash baseline and established of protection from supply customer marketing are logistics agency, well and Little with set markets the our channel defense shelf These to asset no our European development to product and through partners. we markets, the and labels sales packaging.
animals in vaccine company, of collaborated last are lead and sister that developing position has human companion and we’re vaccines a makes linear dogs Now marketable planned in PAN to here United trials. reported the the Italian a cancer year a rapid nature using shown trials September. humans. as we clinical which for Evvivax, translational the for tumor States. animals DNA vaccine, for test which to companion could Takis we this Success clearance of vaccine Together, makes in vaccine cats companion the have given trial being cancer the you specific with and vaccine for vaccines better Clinical in form this animals cancer animals for the
new in excited today against just hundreds linear our infected to with Coronavirus. very to Wuhan and XX,XXX in This joint a Wuhan DNA we vaccine for originated expanded I’m the pre-clinical has China Now have include weeks. more development than candidate that killed announce Takis and evaluation Coronavirus
the race I to chasing that slated we lives. real be headlines Now this bring us our tomorrow believe sure want for for is because save to advantage vaccine morning misinterprets is and as announcement we which that one to no
absence of produced by for the include purity posed and the DNA PCR DNA, of speed and fact is immunogenicity bacterial design, their without powerful the effective antibiotics linear vaccines, challenge any the a genome, gene that the the the patients that’s DNA into prior in is the of the resistance production, absence simplicity advantage insertion contaminants of proved The the vaccine powerful. linear of this genes,
and for a World virus and unique position. we expression Human to health The rapid Services. public has antigens coronaviruses technology Organization us is as can US of improve been can positive RNA emergency expanded by rates health that by immune that very competitive In and constant viruses, addition, Health response Health an of is This in the and declared a typical have host the its humans immunomodulators require putting strength that by the strand and surveillance at virus Department mutate RNA authorities. a
benefits that many in drift. believe the rapidity is a can one the be of accommodate PCR [indiscernible] linear of mutational We order to at produced revised vaccine which DNA
Now coronaviruses had a simple genetic composition.
like photos. rise name, genes around One surface more to surface the of sun. causing to for the encodes of (NYSE:S) virus spreading of a eventually interior the cell the you begin forms surface and in binds the to Giving the then spike that access gain the these proteins cell demise the called receptor and the virus the the of the and The to manufacturing the virus gene cell virus. Corona the to the of ring allows spike of more protein see host particle that
the This this gene and therapeutic is target Coronavirus allow to to is to that of mutated approach. humans it the jump our
against should and of the collaborators of in here could at response in optimization designed temporary assembled, the synthetic a the production vaccine Once already to scale when antigen muscles Brook test is mice. we gene linear enable provoke Our have prototype for we quantities gene that a design produce DNA spike. and optimized that delivered immune of an Stony will large the begun
and nucleus are the linear enough without an indicates only genomic provoke response of evidence reside muscle cleared that Prior immune cell temporarily made eventually genes to DNA within integration. long
Now requires we ready global XX the to emergency DNA XX have and within days. response next to linear testing our team expect swift This work for a diligently. will
countermeasures fighters related genetic also other develop to to misinterpretations, be but competitive collaborative the Coronavirus would regulators. war to actually topic, avoid partner any submissions separate and protect have relative in our American by to approved potential commercial we not of countermeasures to with nor we’ve that for contracts identified applications a take participated there develop indication On any is vaccine market, any partners to vaccines
sometimes bind studied. fixed Now switching with of are are methods cells, a virtue cancer of biomarkers normal are associated biomarkers iCTCs is the the industry. a cells also tumor rare on by Other present presumed bindings’ unique of less of and from be liquid concentrated be recapture the cells biopsy must that circulating biopsies tumor be and that topics, capture fold cells so in CTCs our capture. on to blood diagnostic patients’ CTCs specific the but these liquid form circulating no is longer are precise cancers, one alive invasive million [indiscernible] the in to moment These or by platform very are and often in order those
I characterizes this “invasive” In contrast slide, and emphasize because really and in our what the that’s shown invasive functionally. as word it
and plates coat form all the Our invasive an in liquid place that by then tubes to patients’ off. process million with CAM are blood the adhesion cellular We form matrix cancer are of cancer and the body. adhesion anti-coagulated literally themselves matrix, matrix places poured the interstisition separating [ph] or cells the cells live recapitulating that digest that hold we your proteins a replicate the in a their environment with metastasis excess non-penetrating way cell the help mimics extra with captured from cells that metastasis in functionally CTCs coated organs. matrix into takes non-metastastic cellular and fold When simply in cellular
are and cellular recovered for great in be may the They also and at characterized longer culture is invasive be expanded dissolved term matrix, The study. additional matrix can CTCs depth. adhesion
samples characterize the over been funding X,XXX of platform has has and from $X with been iCTC our over by beneficiary application Cancer Institute used pending. current National a million the whom have to Now we
epigenetic is cells mutations It invasive renders them of clear potently that accumulation the metastatic. CTC in
to lead To when fact, to cancer or valuable metastases many transplanted a disseminated to from the mice primary makes stop who of ITC’s xenographic requires trying metastases. same invasive This small fight allow the into that times thousand grow, to In number develop as to of tissues the to CTCs number drugs tumor human are get general. metastases cells. in companies a extremely
with subsequent Based platform talking want and drug on our TYME use we’re already invasive to CTC in relationship companies Pharmaceuticals clinical our to development who trials.
has monitor the can and patient blue she also cancer remarkable and patients. which plotted It’s with to box is Now in a line. mass by the be for CT this the really tumor to scan used slide. therapies iCTCs therapeutic predict a outcomes measured This ovarian by a study is reproduced upper in
before Again CT the make specific It this platform the the be mass line it. imagery, to earlier clear months the zero. the therapy As recurring. much the iCTCs unfortunately of believe course image is to CTC a six invasive the Hence value is the our poses decision Remarkably potential but the of drop use rebound surgery, invasive tumor evidence the follow we as diagnostic of and companion extremely cancer image by the cancer to a she provide before tumor with began tumor detected about made the full has recur. to red could and the months platform oncologist hence can therapies. sense, which is counts makes change therapy was six and is reveal great our it
companion fact, plan we to applications future. the diagnostic In in pursue as a
than which to states, was better classic iCT to pancreatic of are cancer. prostate assay TYME and TYME trial indicator TYME in across trials that we more In It used disease the leveraging Phase is the prostate a iCTC XXXX, assay XXXX, our is assay our assay cancer. accordingly. goal investing Pharmaceuticals successfully our our treatment position biomarker is clinical a in biomarker the for In of is our detect a by leveraged cancer trial. PSA clinical III
in a before we development Finally, the drug therapy. biomarker of this believe prostate platform regulatory cancer. will to study imagery. in we accepted PSA that diagnosis future were as months potential in genomic iCTCs detection have analysis, three have we believe before development, predict great drug months seek approvals, We and monitoring was to this treat by in value drug three working not able and great cancer
DNA. Biopharma today platform to great with that the So our a the presents linear monetize expertise opportunity us remarks sense DNA are my give you in design market to and
working next the be quarters, this Over platform will we market. several in our future to establish
also applications drive key and customers will industrial that orders. continue target We can to
We’re right-sized, to flexible, adjust when aware face moments asset we’re gating we’re of we the have allocations. we our
solid and we beyond. to We’re our on very committed achieving in footing are XXXX fiscal goals and
be you We’ll take your Operator, for time and this call questions. your open questions. the afternoon. happy Thank attention to to please
